News – Page 2 – Fibrocor Therapeutics

October 20, 2020June 15, 2023News

Fibrocor is pleased to be presenting at TSX Life Sciences Investor Day

October 7, 2020June 15, 2023News

Fibrocor Therapeutics Inc. Announces Appointment of Industry Veteran William C. Fanslow Ph.D., as Senior Vice President Drug Development

TORONTO, CANADA / ACCESSWIRE / OCTOBER 27, 2020 – Fibrocor Therapeutics Inc. (“Fibrocor” or “the Company”), a privately held developer of de novo therapeutics to treat Fibrosis, announced today the appointment of industry veteran William […]

January 15, 2020June 15, 2023News

Fibrocor and Galapagos Sign Expanded Collaboration in Fibrosis

Mechelen, Belgium and Toronto, Canada; 15 January 2020, 7.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) and Fibrocor Therapeutics Inc. (Fibrocor) today announced an expanded collaboration focused on novel targets in fibrosis, with Galapagos […]

December 30, 2018June 15, 2023News

Fibrocor and Galapagos Sign Partnership in Fibrosis

Mechelen, Belgium; December 2018, 22.01 CET – Fibrocor Therapeutics L.P. (Fibrocor), a privately held Canadian company, and Galapagos NV (Euronext & NASDAQ: GLPG) announced a global partnership focused on a novel target for idiopathic pulmonary […]